Recent Quotes (30 days)

You have no recent quotes
chg | %

Antibe Therapeutics Inc  

(Public, CVE:ATE)   Watch this stock  
Find more results for ATE
-0.010 (-9.09%)
Jul 31 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.09 - 0.11
52 week 0.04 - 0.57
Open 0.11
Vol / Avg. 115,100.00/52,784.00
Mkt cap 4.97M
P/E     -
Div/yield     -
EPS -0.12
Shares 49.65M
Beta     -
Inst. own     -

Key stats and ratios

Q1 (Mar '15) 2015
Net profit margin -23852.57% -22049.95%
Operating margin -23852.57% -22049.95%
EBITD margin - -22049.95%
Return on average assets -256.28% -171.22%
Return on average equity -406.20% -240.78%
Employees 3 -
CDP Score - -


15 Prince Arthur Ave

Website links


Antibe Therapeutics Inc. develops and out-licenses protected new pharmaceuticals. The Company’s drug design methodologies involve chemically linking an existing drug (base drug) to an Antibe-patented, hydrogen sulfide-releasing molecule; hydrogen sulfide (H2S) is the key gaseous mediators and has anti-inflammatory, anti-nociceptive (pain-killing) and vasodilatory properties. The Company’s lead compound, ATB-346, combines a gaseous mediator (H2S) with naproxen, a widely used NSAID, to create a novel therapeutic compound. The Company’s drug development pipeline include ATB-346, ATB-344 and other candidates.

Officers and directors

Walter M. Macnee Independent Chairman of the Board
Age: 59
Daniel Legault J.D. President, Chief Executive Officer, Secretary, Director
Age: 56
John L. Wallace Ph.D. Founder, Chief Scientific Officer, Director
Age: 57
Michael Bumby Chief Financial Officer
Age: 50
Jeremy Grushcow Executive Vice President - Strategic Development
David Vaughan Chief Development Officer
Age: 63
Roderick J. Flower Ph.D. Independent Director
Age: 69
Jonathan Ross Goodman Independent Director
Age: 46
Samira Sakhia CPA Chief Financial Officer, Director